ArticleFrontiers in medicine2025
Burden of lung cancer and application of patient-reported outcomes in the Western Pacific Region: a systematic analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of lung cancer and the experiences of patients necessitate attention. This study evaluated the disease burden of lung cancer and the attributes of patient-reported outcomes (PROs) in clinical trials pertaining to lung cancer within the Western Pacific Region (WPRO). Methods: Drawing upon data from the Global Burden of Disease Study (GBD) 2021, the incidence, mortality, and disability-adjusted life years in the WPRO from 1990 to 2021 was retrieved and analyzed. Clinical trial data conducted within the WPRO spanning from 2010 to 2022 were extracted from International Clinical Trials Registry Platform, encompassing trial phases, study settings, participant demographics, and PRO instruments. Trials were categorized into three groups based on the mention of PRO usage and the utilization of specified PRO instruments. Results: In 2021, the WPRO witnessed 1.15 million (95% UI 0.96-1.36) new lung cancer cases and 0.99 million (95% UI 0.82-1.16) deaths. From 1990 to 2021, Singapore showed the most pronounced decline in the age standardized incidence (-38.62, 95% UI -46.63 to -30.99), while China was experiencing the highest increase (32.92, 95% UI 1.21-71.31). Among the 3,889 trials examined, 24.48% trials employed PRO instruments as outcome measures. A majority of these PRO-related trials were conducted in China, Japan, Australia and South Korea, with frequently used PRO instruments including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Lung Cancer 13, and the Visual Analogue Scale. Conclusion: Marked disparities existed in the lung cancer burden among the individual countries in the WPRO. There is a pressing need to allocate further resources toward the implementation of standardized, condition-specific PROs and strategies aimed at minimizing the lung cancer burden, especially in low and low-middle SDI countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.